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ABSTRACT
This article reports the development of a method for genotyping Chlamydia trachomatis, using PCR and
sequencing of omp1, supplemented with three new variable number tandem repeat (VNTR) loci of
C. trachomatis. Typeability, reproducibility and discriminatory power were assessed using four groups
of samples: two groups (I and II) of C. trachomatis-positive patients and their positive partner(s), one
group (III) of patients with recurrent or persistent C. trachomatis infections, and one group (IV)
comprising samples containing a newly discovered mutant strain with a 377-bp deletion in the cryptic
plasmid, the new variant C. trachomatis (nvCT). The VNTR loci (designated CT1335, CT1299, and
CT1291) were all single nucleotide repeats chosen for maximal mutability and variation. In the study
material, nine variants of CT1335, eight variants of CT1299 and five variants of CT1291 were found. The
discriminatory power (D) of omp1 in the present material was Domp1 = 0.69. Ds for VNTRs CT1335,
CT1299 and CT1291 were 0.53, 0.74 and 0.74, respectively. The resolution power of the omp1-VNTR
assay was 0.94. Stability over time of the VNTRs was investigated and found to be adequate for
epidemiological studies. Using this genotyping assay, it was confirmed that the nvCT strain was indeed
a clone. These results indicate that, with this novel method, strains of C. trachomatis can be individually
identified, and epidemiological associations established.
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INTRODUCTION
Chlamydia trachomatis is a pathogen that is
frequently sexually transmitted worldwide. In
Denmark and the other Nordic countries, the
spread of C. trachomatis is endemic in the age
group 15–25 years [1–4], despite intensive efforts
to reduce the spread, e.g. by information and
partner tracing [1,2,4–6]. Infection with C. tracho-
matis may be followed by serious sequelae such as
ectopic pregnancy or tubal infertility. Recently, it
has been indicated that complication rates may
have been overestimated [7]. However, the num-
ber of in vitro fertilizations, which may reflect
infertility caused by past C. trachomatis infection,
is increasing [8]. The epidemiology of C. trachoma-
tis has been addressed with different typing
systems. Initially, serotyping of the major outer-
membrane protein (MOMP) was used [9,10], but
since PCR-based assays have been developed,
restriction fragment length polymorphism [11–
14], and PCR and sequencing of omp1 (the gene
coding for MOMP), have been the methods of
choice [5,15–20]. Restriction fragment length poly-
morphism, in contrast to omp1 sequencing, is able
to reveal mixed infections as shown by the
restriction patterns. The drawback of the method
is that it does not allow for identification of single
nucleotide changes, which are the most predom-
inant variations in omp1 [5,15–20]. Also, gel-to-
gel variation and inter-laboratory differences
make comparison of results among laboratories
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difficult. The omp1 PCR and sequencing is easily
compared among laboratories, but fails to identify
mixed infections, since sequencing of a mixed
product cannot be unambiguously interpreted.
Both methods, however, lack discriminatory
power to identify differences within a given
omp1 genotype and to determine the cause of
recurrence [19].
Persistent infections are interesting, not only
because they may lead to sequelae, but impor-
tantly, because they represent a significant source
of further transmission. A large percentage of
C. trachomatis-positive patients experience recur-
rent infections [19,21]. In a follow-up study, it was
found that after PCR-verified clearance of the
infection, C. trachomatis was present again after
24 weeks in 29% of the initially C. trachomatis-
positive patients [19].
Multilocus sequence typing (MLST) of C. tracho-
matis has recently been proposed for genotyping
[22]. This approach addresses the sequences of a
number of housekeeping genes, which are known
to be genetically stable due to their pivotal role in
cell survival. The MLST typing method, therefore,
is suited for long-term, as well as global, epide-
miology. In the present study, variable number
tandem repeats (VNTRs), which are defined as
repeated stretches of the same nucleotide or
motifs, were studied. It is known that, in these
areas of repetition, DNA polymerase is prone to
error during replication. This is especially true for
single nucleotide repeats [23,24], which is why this
type of target is suited for short-term, local
epidemiology, and has hence been chosen for this
study. Analysis of several VNTR targets will result
in high resolution power. In the present article, the
development of a genotyping assay targeting omp1
and three VNTR loci, which can be used for
individual identification and genotyping of strains
of C. trachomatis, is reported.
MATERIALS AND METHODS
Target finding and primer design
The whole genome of C. trachomatis strain D ⁄UW-3 ⁄CX,
accession number NC000117, was investigated for maximal
tandem repeats by the use of mreps 2.1 (http://bioweb.
pasteur.fr/seqanal/interfaces/mreps.html). Standard settings
of the mreps 2.1 program were used, modified with ‘repeats
of 10 or more nucleotides’ and ‘output small repeats that can
occur randomly (-allowsmall)’. These small DNA stretches
were chosen because of the low degree of variation in the
C. trachomatis genomes. In a pilot study, the method was tested
on 18 randomly selected urine samples to initially assess the
variability of the VNTRs (poster D-475, ICAAC, 2004). Of
these, nine showed genetic variation that was too low to be
useful in genotyping: the loci CT1359 (10T), CT1352 (10A),
CT1344 (10T), CT1319 (CAGCAGCAGCAGC), CT1325 (7TG6T
and 5TC6T), CT1323 (10T), CT1333 (8AT7A) and CT1334
(GAGAGAGAGAG) were rejected, since some of the targets
showed no variation in the 18 samples (comprising D, Da, E, F
and K omp1 genotypes), and the maximal variability of these
VNTRs was two different variants. Three VNTRs—CT1291,
CT1299, and CT1335—were found to have very high
discriminatory power, and were chosen for further studies.
Primers for PCR were designed using the Primer3 soft-
ware (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_
www.cgi). Nested PCR for omp1 [16] and regular PCR for
candidate VNTRs were performed on a PrimusHT thermocy-
cler (MWG BIOTECH, Ebersberg, Germany). Primers for
VNTRs are listed in Table 1.
Clinical samples
An overview of the four groups of samples included in the
study is given in Table 2.
Group I. In Aarhus County, partner tracing was routine among
C. trachomatis patients aged 15–25 years. ‘Partners’ were
defined as the patient’s self-reported sexual relationships
within the past 12 months. As part of the project, both parties
Table 1. Primers for variable
number tandem repeat PCR
Nucleotide
positiona
CT1291 forward: GCC AAG AAA AAC ATG CTG GT 195 536–195 555c
CT1291 reverse: AGG ATA TTT CCC TCA GTT ATT CG 195 760–195 738
PCR product size: 225 bpb
CT1299 forward: TTG TGT AAA GAG GGT CTA TCT CCA 291 758–291 781d
CT1299 reverse: AAG TCC ACG TTG TCA TTG TAC G 291 945–291 924
PCR product size: 188 bp
CT1335 forward: TCA TAA AAG TTA AAT GAA GAG GGA CT 737 225–737 250e
CT1335 reverse: TAA TCT TGG CTG GGG ATT CA 737 377–737 358
PCR product size: 153 bp
aIn D ⁄UW-3 ⁄CX, accession number NC 000117.
bIn some samples, the size was c. 510 bp.
cForward primer in CT172 hypothetical protein, reverse primer in CT172.1 hypothetical protein, actual repeat at
nucleotides 145–154 in the 171-bp gene for hypothetical protein CT172.1.
dNon-coding region.
eNon-coding region plus first 43 bp of Gene ID 884426 DNA topoisomerase I ⁄ SWI domain fusion protein. Actual
repeat –44 to –61 of Gene ID 884426 DNA topoisomerase I ⁄ SWI.
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were asked to submit a home-obtained sample for C. tracho-
matis testing. From this group, 99 samples from 49 couples
were included, since one index patient had two C. trachomatis-
positive partners.
Group II. A further 23 couples, in which both parties were
C. trachomatis-positive, were identified in the routine labora-
tory database. The inclusion criteria were that they shared
the same postal address, and that there was a difference in
age <15 years between the two parties (increasing the
probability of them actually being a couple).
Group III. Twenty-four patients who experienced recurrent
C. trachomatis infections, i.e. who had ‡2 C. trachomatis-
positive samples taken ‡2 months apart, and showing the
same omp1 type in consecutive samples, were identified. The
samples were identified in a collection of frozen clinical
samples, containing C. trachomatis-positive samples from
patients tested during previous years.
Group IV. Thirty-three samples belonging to the recently des-
cribed mutant strain with a 377-bp deletion in the cryptic
plasmid [4] were collected in Malmo¨, Sweden from November
2006 to February 2007, where the new variant C. trachomatis
strain at that time comprised 27% of the Chlamydia-positive
samples. The deletion was verified by a commercially available
real-time PCR (TIB MOLBIOL, Berlin, Germany), and an in-
house PCR (LNP, personal communication), both specific for
the mutant strain.
For all four groups, the included material consisted of urine
samples from males, and cervical and ⁄ or urethral swabs from
females.
DNA isolation
First void urine (200 lL) or 200 lL of swab specimen in
transport buffer (GEN-PROBE, San Diego, CA, USA) was
purified using the MagNAPure Compact, and the Total NA kit
(Roche, Hvidovre, Denmark), according to the manufacturer’s
instructions. The elution volume was 50 lL.
PCR reactions
The omp1 gene was amplified as described previously [16].
PCR conditions for all three VNTRs were: 10 min at 94C, and
40 cycles (45 s at 94C, 45 s at 56C, and 45 s at 72C). VNTR
reactions were performed in 50 lL using 100 pmol of each
primer, 5 mM MgCl2, 1.25 lM each dNTP, 2.5 U of AmpliTaq
Gold and Gold Buffer II (Applied Biosystems, Naerum, Den-
mark). The generally recommended precautions for limiting
cross-contamination were taken [25].
Table 2. Genotype distribution and overview of patient groups included in the study
Group
I: Self-reported partners II: Shared address III: Recurrent ⁄ resistant infections IV: Swedish deletion mutant clone
Number of patients includeda 91 (45 couplesb) 46 (23 couplesb) 24b 33 (1b)
Age distribution (years) 17–25 (index)
(mean 21.5)
18–42 (partner)
(mean 23.1)
18–48 (mean 26.7) 18–32 (mean 23.3) 15–40 (mean 22.5)
Omp1 distribution E: 37 ⁄ 91 (41%) E: 24 ⁄ 46 (52%) E: 16 ⁄ 24 (67%) E: 33 ⁄ 33 (100%)
K: 14 ⁄ 91 (15%) F: 7 ⁄ 46 (16%) F: 5 ⁄ 24 (21%)
D-B: 13 ⁄ 91 (14%) D-IC: 5 ⁄ 46 (11%) Ia: 1 ⁄ 24 (4%)
F: 10 ⁄ 91 (11%) D-B: 4 ⁄ 46 (9%) K: 1 ⁄ 24 (4%)
G: 8 ⁄ 91 (9%) J: 2 ⁄ 46 (4%) D-B: 1 ⁄ 24 (4%)
J: 7 ⁄ 91 (8%) K: 2 ⁄ 46 (4%)
H: 1 ⁄ 91 (1%) H: 1 ⁄ 46 (2%)
D-IC: 1 ⁄ 91 (1%) B-IU: 1 ⁄ 46 (2%)
CT1335 type 1: 4 ⁄ 91 (4%) 1: 1 ⁄ 46 (2%) 1: – 1: –
2: 5 ⁄ 91 (6%) 2: 3 ⁄ 46 (7%) 2: – 2: –
3: 41 ⁄ 91 (45%) 3: 6 ⁄ 46 (13%) 3: 3 ⁄ 24 (12%) 3: –
4: 1 ⁄ 91 (1%) 4: – 4: – 4: –
5: 1 ⁄ 91 (1%) 5: – 5. – 5: –
6: 6 ⁄ 91 (7%) 6: – 6: – 6: –
7: 1 ⁄ 91 (1%) 7: – 7: – 7: 1 ⁄ 33 (3%)
8: 32 ⁄ 91 (35%) 8: 34 ⁄ 46 (74%) 8: 21 ⁄ 24 (88%) 8: 32 ⁄ 33 (97%)
9: – 9: 2 ⁄ 46 (4%) 9: – 9: –
CT1299 type 1: 2 ⁄ 91 (2%) 1: 1 ⁄ 46 (2%) 1: – 1: –
2: 6 ⁄ 91 (7%) 2: 1 ⁄ 46 (2%) 2: – 2: –
3: 6 ⁄ 91 (7%) 3: 3 ⁄ 46 (7%) 3: – 3: –
4: 27 ⁄ 91 (30%) 4: 1 ⁄ 46 (2%) 4: 3 ⁄ 24 (12%) 4: –
5: 27 ⁄ 91 (30%) 5: 17 ⁄ 46 (38%) 5: 11 ⁄ 24 (47%) 5: –
6: 21 ⁄ 91 (22%) 6: 19 ⁄ 46 (41%) 6: 8 ⁄ 24 (33%) 6: –
7: – 7: – 7: 1 ⁄ 24 (4%) 7: 33 ⁄ 33 (100%)
8: 2 ⁄ 91 (2%) 8: 2 ⁄ 46 (4%) 8: 1 ⁄ 24 (4%) 8: –
NT: 2 ⁄ 46 (4%)
CT1291 type 1: 21 ⁄ 91 (22%) 1: 21 ⁄ 46 (46%) 1: 14 ⁄ 24 (59%) 1: 33 ⁄ 33 (100%)
2: 20 ⁄ 91 (22%) 2: 14 ⁄ 46 (31%) 2: 7 ⁄ 24 (29%) 2: –
3: 31 ⁄ 91 (34%) 3: 6 ⁄ 46 (13%) 3: – 3: –
4: 12 ⁄ 91 (14%) 4: 2 ⁄ 46 (4%) 4: 2 ⁄ 24 (8%) 4: –
5: 7 ⁄ 91 (8%) 5: 2 ⁄ 46 (4%) 5: 1 ⁄ 24 (4%) 5: –
NT: 1 ⁄ 46 (2%)
aAfter exclusion of omp1 non-typeable samples.
bOne patient per couple in Groups I and II was used for the calculation of the discriminatory power, plus all samples from Group III and one from Group IV. All samples were
epidemiologically independent.
NT, non-typeable.
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PCR product purification
PCR products were purified before sequencing was
performed. For the VNTRs CT1299 and CT1335, this was
done directly on the fluid without prior gel analysis using
the QIAquick PCR Purification Kit (QIAgen, Ballerup,
Denmark). For VNTR CT1291, the PCR products were
applied to an agarose 2% (w ⁄v) gel, due to unspecific
product formation, which could interfere with the sequenc-
ing reactions. The band of the expected size was excised,
and DNA was purified using the QIAquick Gel Extraction
Kit (QIAgen, Ballerup, Denmark). In some strains, the
CT1291 band was 225 bp, and in others c. 510 bp (Table 1).
Sequencing showed that an insertion mutation had occurred
in this VNTR region.
Sequencing
Sequencing reactions were performed with the BigDye v 3.1
Cycle Sequencing Kit (Applied Biosystems), according to the
manufacturer’s instructions, except that 6 lL of mastermix and
4 lL of template was used. The reactions were subsequently
run on an ABI PRISM 3100 sequencer (Applied Biosystems).
The omp1 gene was sequenced once with the forward
primer, and once with the reverse primer, creating an overlap
of c. 250 bp in the mid-region. Omp1 sequences were then
genotyped using the nucleotide BLAST two sequences
approach (NCBI). Accession numbers for the omp1 reference
types used are A, M58938 M33535; B-IU, AF063208; B-TW,
M17342 M19127; C, M17343 M19128; D-B, X62918; D-IC,
X62920; E, X52557; F, X52080 M30501; G, AF063199; H,
X16007; I, AF063200; Ia, AF063201; J, AF063202; Ja, AF063203;
K, AF063204; L1, M36533; L2, M14738 M19126; and L3, X55700.
In cases of discrepancy with the reference omp1 type (putative
mutations), PCR and sequencing were repeated.
Sequences of the VNTRs (only the repeated part of the
sequences) were visually investigated for differences by two of
the researchers (LNP and LP). For Group I, all PCR and
sequencing reactions were carried out in duplicate to avoid
reporting differences due to Taq polymerase errors. In cases of
discrepancy between the two results, PCR and sequencing
were repeated. For Group II, the scheme was simplified to
PCR and sequencing once. Only in cases of discrepancy
between results from the two partners were PCR and sequenc-
ing repeated. For Group III, the scheme was simplified even
further, since only patients with a persistent omp1 type were of
value in the assessment of VNTR stability. Thus, VNTR
analyses were performed only if the patient had two or more
samples with the same omp1 type. All samples from Group IV
were analyzed by PCR and sequencing once, except one
discrepant sample, for which PCR and sequencing were
repeated two additional times.
Assigning a VNTR genotype
For each VNTR, a new type, equivalent to the number of
repeated mononucleotides, was given a random number.
Continuous numbers, starting with 1, were chosen. The
resulting VNTR genotype is a three-digit name composed of
the number of the repeat type found within each of the three
VNTR loci, CT1335, CT1299 and CT1291. This numbering
system was chosen because it is in line with the numbering
system used for the established genotyping method, MLST
(http://www.mlst.net). A conservative approach was chosen,
and a new genotype was defined only when at least one
nucleotide in each of two different targets was present. The
different VNTR types found in this study are shown in Table 5.
Specificity
The specificity of the VNTR assay was investigated by PCR of
ten C. trachomatis-negative clinical samples, human DNA
isolated from buffy coat, and DNA from 11 different bacterial
species: Neisseria gonorrhoeae, Escherichia coli, Streptococcus
pyogenes, Enterococcus faecalis, Klebsiella pneumoniae, Gardnerella
sp., Lactobacillus sp., Candida albicans, Chlamydophila pneumo-
niae, Mycoplasma genitalium, and Mycoplasma pneumoniae.
Discriminatory power, typeability and reproducibility
Discriminatory power was calculated as recommended by
Hunter and Gaston [26,27], and is reported for omp1 and each
of the three VNTRs, plus the combined discriminatory power
for all four targets, i.e. the discriminatory power for the assay:
D ¼ 1 1
NðN  1Þ
XS
j¼1
njðnj  1Þ
where D is the index of discriminatory power, N the number of
unrelated strains tested, S the number of different types, and nj
the number of strains belonging to the jth type. Since D must
be based on epidemiologically unrelated samples, only results
from the 45 index patients of Group I, one patient per couple
in Group II (23 patients) and all patients of Group III with the
same omp1 type on more than one occasion (24 patients), plus
one patient from Group IV, were included in the calculation of
the discriminatory power. Thus, samples from 93 epidemio-
logically unrelated C. trachomatis patients have been used for
the calculation of D; see Table 2. Typeability (T) was calcu-
lated for the VNTRs alone, since the omp1 gene is present in all
C. trachomatis strains. Thus, T is based on all 194 patients
included in the study (Groups I–IV, Table 2).
T ¼ Nt
N
where Nt is the number of isolates assigned a type, and N the
number of isolates tested [28,29]. As for T, the reproducibil-
ity (R) was calculated for the three VNTRs.
R ¼ Nt
N
where Nt is the number of isolates assigned the same type on
repeat testing, and N the number of isolates tested [28,29].
RESULTS
Group I: four of the 99 initially selected C. tra-
chomatis-positive samples from the 49 couples in
Group I (one person had two positive partners)
could not be assigned an omp1 type. The samples
from these four patients and their partners were
therefore excluded from the study, leaving 45
couples in Group I (91 samples). For Groups I
and II, the omp1 genotype distribution and point
mutations (equalling omp1 inter-genotype varia-
tion), as well as individual VNTR genotypes, are
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shown in Tables 3 and 4, respectively. Notably,
12 (27%) of the 45 couples tested in Group I did
not share the same omp1 genotype. Of the
remaining 33 couples, 21 couples shared exactly
the same genotype, both omp1 and all three
VNTRs. This leaves 12 couples who shared the
same omp1 genotype but had different VNTRs. Of
these, five couples had differences in two VNTRs,
and seven couples had differences in one VNTR.
None had differences in all three VNTRs.
Group II (shared address): among 23 couples
and 46 samples, one couple (no. 59) could not be
assigned a CT1299 type, and one of the parties in
one couple (no. 68) could not be assigned a
CT1291 type. These VNTRs are listed in Table 4
as non-typeable. In this group, 19 ⁄ 23 (83%)
couples shared the same genotype. Of these, four
(17%) couples had different omp1 genotypes.
Three couples had one difference in one VNTR,
and no couples had two or more differences in
VNTRs.
In Group III (possible persistent infection),
comprising 24 patients, all patients (according to
definition) had unchanged VNTRs during the
time of infection, although two patients had one
difference in one VNTR. C. trachomatis was pres-
ent in these patients for between 70 and 394 days,
with an average of 153 days, assuming that
C. trachomatis was indeed present throughout
the entire period of time, and not only at the
times of sampling. The genotype distribution is
shown in Table 2.
Table 3. Overall distribution of omp1 and mutations
therein plus variable number tandem repeat (VNTR)
types: Group I, self-reported partners
Couple no. omp1 type; mutations VNTR typea
Partners with the same omp1-VNTR genotype
1 K 3.2.3
2 K 3.3.4
3 K 3.3.4
4 K 3.2.3
5 K 3.3.5
6 K 3.2.3
7 E 8.5.1
8 E: 243A>G,
246C>T, 247C>G
8.6.2
9 E 8.6.1
10 E 8.5.1
11 E 8.5.1
12 E 8.6.1
13 E 8.6.1
14 E 8.5.2
15 D-B 2.4.5
16 D-B 1.4.3
17 J: 360G>A 3.8.3
18 J: 186G>A 3.4.4
19 J 3.1.3
20 G: 228T>A; 487G>A,
700G>C, 1003T>A
3.5.5
21 G: 228T>A; 487G>A,
700G>C, 1003T>A
3.5.3
Partners with same omp1 genotype and one difference in VNTRs
22 G: 1003T>G 3.4.4 vs. 3.6.4
23 E 8.5.1 vs. 3.5.1
24 F 8.6.2 vs. 3.6.2
25 D-B: 269G>A 6.4.2 vs. 3.4.2
26 D-B 1.4.3 vs. 1.5.3
27 E 8.5.3 vs. 3.5.3
28 E 8.4.1 vs. 8.4.3
29 F 8.6.2 vs. 8.4.2
Partners with same omp1 genotype and two differences in VNTRs
30 E 8.6.2 vs. 2.4.2
31 E 6.5.1 vs. 6.4.2
32 E 8.5.1 vs. 3.5.3
33 E 8.6.2 vs. 3.6.3
34 E 2.6.3 vs. 3.6.1
Partners with different omp1 genotype and VNTRs
35 D-B: 1091G>A, 1109G>A vs.
H: 440A>G, 1018C>A
2.4.4 vs. 3.4.3
36 G: 1003T>G vs. K 3.4.3. vs. 3.4.3
37 E vs. D-B 8.5.1 vs. 8.4.3
38 K vs. F 3.4.4 vs. 6.4.2
39 D-IC: 601A>G vs.
D-B: 1093T>C
8.4.3 vs. 3.4.3
40 D-Bb vs. D-B:
1091G>A, 1109G>A
2.4.5 vs. 7.4.5
41 F vs. E 8.5.2 vs. 6.5.3
42 E vs. G: 1003T>G 8.6.1 vs. 3.4.3
43 F vs. F: 1162G>A 8.6.2 vs. 3.4.2
44 D-B vs. E 3.5c.4 vs. 3.5.1
45 F vs. E 6.6.2 vs. 4.5.4
46 J vs. F 5.6.3 vs. 3.5.2
aVNTR types described in Table 3, numbered: CT1335 variant, CT1299 variant,
CT1291 variant.
bThis individual was also a partner in couple no. 15.
cVNTR type 5 with a C>G mutation at position 5.
Table 4. Overall distribution of omp1 and mutations
therein plus variable number tandem repeat (VNTR)
types: Group II, alleged partners with same postal address
Couple no. omp1 type; mutations VNTR typea
Partners with same omp1-VNTR genotype
47 E 8.5.2
48 E 9.6.1
49 E 8.6.1
50 E 8.6.2
51 E 8.6.1
52 E 8.6.1
53 E 8.5.1
54 E 8.6.1
55 E 8.5.1
56 E 8.5.1
57 D-IC 8.5.2
58 D-IC 8.5.1
59 D-B 3.NT.4
60 D-B 3.3.5
61 F 8.6.2
62 J 3.8.3
Partners with same omp1 genotype and one difference in VNTRs
63 F 8.6.1 vs. 8.6.2
64 E 8.5.2 vs. 8.5.1
65 F 8.6.2 vs. 8.5.2
Partners with same omp1 genotype and two differences in VNTRs
None
Partners with different omp1 genotypes and VNTRs
66 K vs. F 2.2.2 vs. 8.6.3
67 K vs. H 2.1.3 vs. 2.3.3
68 E vs. D-IC 8.5.NT vs. 8.6.2
69 E vs. B-IU 8.5.1 + 3b vs. 1.4.3
aVNTR types described in Table 3, numbered: CT1335 variant, CT1299 variant,
CT1291 variant.
bThis patient had PCR products of both 224 and 510 bp in the CT1291 VNTR.
NT, non-typeable.
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Group IV (deletion mutant): the genotype dis-
tribution is shown in Table 2. Note that one
sample showed a 1-bp deletion in CT1335. All
other samples were identical at all four sites
tested.
The numbers of different VNTR types identi-
fied were: CT1335, 9; CT1299, 8; and CT1291, 5;
see Table 5.
Specificity of VNTR PCR
Unspecific bands occurred on the gels when some
of the non-chlamydial bacteria were analyzed. In
a few cases, bands corresponding in size to some
of the VNTRs were seen, but sequencing of these
products revealed no similarity to the VNTR
sequences.
Typeability, reproducibility, and discriminatory
power
Typeability and reproducibility of the omp1 gene
is 100%, since the MOMP are present on the
surface of all C. trachomatis cells. For the VNTRs,
the typeability was TVNTRs = 99% (192 ⁄ 194), since
one couple could not be assigned a CT1299 type
(no. 59), and one couple could not be assigned a
CT1291 type (no. 68). All PCR and sequencing
results could be reproduced, and reproducibility
for the VNTRs was thjerefore RVNTRs = 100%. The
discriminatory power (D) was calculated using 93
epidemiologically unrelated samples (see
Table 2). The individual Ds of the chosen targets
were: Domp1 = 0.69, DCT1335 = 0.53, DCT1299 = 0.74
and DCT1291 = 0.74. The discriminatory power of
the assay, equalling the combined Ds of omp1 and
the VNTRs, was DVNTRs + omp1 = 0.94.
DISCUSSION
This article describes a novel genotyping method
using PCR and sequencing of omp1 and three
VNTR loci of C. trachomatis. The overall results,
with a high discriminatory index of 0.94, indicate
that strains of C. trachomatis can be individually
identified using this approach.
Four different groups were investigated. The
main findings were that in Group I (self-reported
partners), different genotypes were frequently
found even at the low-resolution omp1 level. This
shows that self-reporting of sexual partners is not
always done truthfully. The findings were in
contrast to Group II (shared postal address),
where the majority of people living together also
shared the same omp1-VNTR genotype. Group III
showed that the chosen VNTRs are stable and can
be useful for epidemiology. This was reinforced
by Group IV, where it was also shown that
evolution of the VNTRs is progressing.
A surprisingly large proportion of the (alleged)
partners of Group I did not share the same
genotype. This could be explained by the fact
that the samples in Group I were not collected in
a project directly designed for the purpose of
establishing this genotyping method, but during
the implementation of a routine partner notifica-
tion procedure. In this procedure, the index
patients notified their partner(s) (anonymously if
preferred) by mailing them a clarifying letter, a kit
for home-sampling, and a pre-addressed and pre-
stamped envelope. The partners were defined by
the index patients who self-reported sexual rela-
tionships within the past 12 months. Thus, precise
information on the correlation between time of
sexual relations and sampling of test material
cannot be specified further than <1 year. During
this undefined time span, infection from a differ-
ent partner could have taken place. Furthermore,
the epidemiological relatedness of the tested
samples cannot be established firmly, since they
are based solely on statements of the patients.
Thus, the delicate nature of sexual relationships
may influence the situation; i.e., the alleged
partners may not in all cases be ‘true’ partners,
which may explain in part the surprisingly large
proportion of different omp1 genotypes between
partners of Group I. The omp1 gene is well-
characterized, which makes assignment of an
Table 5. Types and variants of the variable number tandem repeats (VNTRs), described in the study
VNTR type Variant number of VNTR type and corresponding repeat sequence
CT1335 1 9T8A 2 10T7A 3 10T8A 4 11T7A 5 11T8A 6 12T7A 7 12T8A 8 13T7A 9 13T6A
CT1299 1 7C 2 8C 3 9C 4 10C 5 11Ca 6 12C 7 13C 8 14C
CT1291 1 6C 2 8C 3 9C 4 10C 5 11C
aOne strain had a C>G mutation at the fifth position.
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omp1 genotype straightforward when based on
the genetic variation among the different omp1
types [16]. This allows for a clear distinction
between the omp1 genotypes by sequencing of the
PCR product. Therefore, 12 individuals must have
been infected by someone other than their self-
reported recent or present partner. Four samples
could not be omp1 genotyped, although they were
initially found to be C. trachomatis-positive. This
could be due to lack of sensitivity of the omp1 PCR
assay as compared with the GEN-PROBE Apti-
ma Combo 2 assay initially used to screen the
samples.
A substantially larger proportion of samples
from Group II shared the same omp1 genotype.
Samples in Group II were collected after a search
in the routine laboratory database for C. tracho-
matis-positive patients with the same postal
address. Living together presumably implies a
monogamous relationship, which may explain
this difference between the two groups. Three
couples had one difference in one VNTR, and
according to the conservatively set standard, this
has been interpreted as the same genotype. Thus,
19 ⁄ 23 (83%) couples living together shared the
same genotype, and only four couples (17%) had
different omp1 types. Naturally, a shared address
will in some cases reflect a sexual relationship,
and in others it may not. This may explain the
differences in the omp1 in the four ‘couples’.
Notably, the samples were found via a database
search, and patients have not been interviewed
about their possible mutual sexual relationship. In
Group II, no couples had two or more differences
in VNTRs.
Regarding the variation in the VNTRs, it can be
argued that a one-nucleotide difference in one
VNTR may not represent a different genotype,
since the repeated nucleotide sequences in
VNTRs, and especially in single nucleotide
repeats, are known to promote polymerase errors
during replication [23,24]. Naturally, this is a
matter of definition, but here, a conservative
approach was chosen and a new genotype was
defined only if there was at least one nucleotide
difference in each of two different targets.
A conservative estimate of individuals in Group I
not infected by their alleged partners would thus
be the 12 ‘couples’ with different omp1 genotypes
plus the five ‘couples’ with differences in two
VNTRs. In total, 17 ⁄ 45 (38%) couples fall into this
category. If insertion or deletion of one nucleotide
in one VNTR were defined as representing a new
genotype, 24 ⁄ 45 (53%) of the partners would
present different genotypes (omp1 and VNTRs).
This, however, is judged to be too wide an
interpretation of these first results with the pres-
ent genotyping method. Yet, these results confirm
that partner tracing based solely on molecular
typing of omp1 has too little discriminatory power
for valid epidemiological use.
The stability of the VNTRs was assessed in
Group III in 24 patients with recurrent or persis-
tent C. trachomatis infections. Thus, stability was
assessed in vivo, which probably results in more
reliable results than in vitro culturing, since the
latter method is without individual selection
pressure from the host immune system and from
possible antibiotic treatment. Furthermore, labo-
ratory strains of C. trachomatis may be adapted to
culturing conditions, in contrast to wild-type
clinical isolates. These 24 patients had stable
omp1 genotypes and, notably, also stable VNTRs
for periods between 70 and 394 days. In five
cases, cervical as well as urethral swabs were
available and were C. trachomatis-positive. Both
were genotyped, and in all cases exactly the same
genotype was recovered from the two paired
samples, which also implies stability of the chosen
VNTRs (data not shown). Furthermore, the geno-
types determined in three cases of positive eye
swabs from newborn infants were compared to
the maternal genotypes; all three paired samples
were identical in genotype (data not shown).
Group IV: this group consists of new variant
C. trachomatis samples from Sweden that seem to
constitute a clone, as determined also by the
present genotyping method. Only one sample had
one difference in one VNTR (CT1335), which
shows that the chosen VNTR loci do change over
time, and also indicates that the conservative
approach for defining a new genotype is valid.
The combined results strongly indicate that the
VNTRs chosen are sufficiently stable but also
sufficiently variable for epidemiological analyses
of C. trachomatis. The excellent reproducibility
(100%) of the VNTRs shows that the variations
are indeed variations, and not errors made by Taq
polymerase.
A drawback of the assay is its inability to
reveal mixed infections. In the sample from index
patient 69 of Group II, two CT1291s are found
(Table 4), which could be explained if the patient
was infected with two different omp1 E types.
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Certainly, more patients could be unrecognizably
infected with more than one genotype. If a large
amount of a certain omp1 genotype of C. tracho-
matis is present and a small amount of another,
the PCR would probably favour the genotype of
larger concentration, and the other genotype
might not be found. Also, when using a PCR
and sequencing approach, mixed genotypes will
create mixed sequences, and peaks from the
different PCR products will be superposed. This
obstacle could be overcome by genovar-specific
PCR of the omp1 gene, or perhaps by denaturing
gradient gel electrophoresis applied to the
PCR products in order to separate the different
genovars by size and charge [30,31]. These
methods have not yet been established in this
laboratory.
The genetic location of the VNTRs needs to be
considered, since functional aspects of repetitive
DNA have been found in a number of microor-
ganisms, e.g. Neisseria meningitidis [32], Streptococ-
cus pneumoniae [33], and Haemophilus influenzae
[34]. Since the A- and T-containing repeated
sequence, CT1335, is located at –44 to –66 of the
DNA topoisomerase I ⁄ SWI domain fusion pro-
tein (gene ID 884426), it could be speculated that a
variation in this sequence may be involved in the
regulation of the transcription of the topoisomer-
ase gene, and possibly in C. trachomatis phase
variation. This is acknowledged, but it was
beyond the scope of this article to elaborate on
this matter. The VNTR CT1299 is located in a non-
coding area, and the VNTR 1291 is located within
the gene for the hypothetical protein CT172.1.
This may indicate that survival of the organism is
not strongly dependent on genetic stability in
these sequences, and so C. trachomatis possibly
tolerates variations in these areas. The location of
the VNTR genes may also explain why the
typeability of the VNTRs was only 98%, since
VNTR CT1299 could not be amplified in one
couple, and CT1291 could not be amplified in one
individual. This negative PCR could be due to
deletion of the target, or it could be due to
mutation(s) in the primer-binding site(s).
In conclusion, an apparently stable and useable
method with a high degree of discriminatory
power for molecular epidemiological studies on
C. trachomatis has been developed and validated.
It will be interesting to gain more knowledge of
the value of this assay from other users, and in
other epidemiological settings.
ACKNOWLEDGEMENTS
The authors would like to thank J. Skov Jensen, State Serum
Institute, Copenhagen, Denmark for inspiring discussions and
support during the process of this study. Samples were kindly
provided by K. Persson, Department of Clinical Microbiology,
Malmo¨ University Hospital, Malmo¨, Sweden.
TRANSPARENCY DECLARATION
The authors declare that they have no conflicting interests in
relation to this work.
REFERENCES
1. Andersen B, Ostergaard L, Moller JK, Olesen F. Home
sampling versus conventional contact tracing for detecting
Chlamydia trachomatis infection in male partners of infected
women: randomised study. BMJ 1998; 316: 350–351.
2. Andersen B, Ostergaard L, Nygard B, Olesen F. Urogenital
Chlamydia trachomatis infections in general practice: diag-
nosis, treatment, follow-up and contact tracing. Fam Pract
1998; 15: 223–228.
3. Moller JK, Andersen B, Olesen F, Ostergaard L. Reasons for
Chlamydia trachomatis testing and the associated age-specific
prevalences. Scand J Clin Lab Invest 2003; 63: 339–345.
4. Ripa T, Nilsson PA. A Chlamydia trachomatis strain with a
377-bp deletion in the cryptic plasmid causing false-neg-
ative nucleic acid amplification tests. Sex Transm Dis 2007;
34: 255–256.
5. Falk L, Lindberg M, Jurstrand M, Backman A, Olcen P,
Fredlund H. Genotyping of Chlamydia trachomatis would
improve contact tracing. Sex Transm Dis 2003; 30: 205–210.
6. Ostergaard L, Andersen B, Moller JK, Olesen F, Worm
AM. Managing partners of people diagnosed with Chla-
mydia trachomatis: a comparison of two partner testing
methods. Sex Transm Infect 2003; 79: 358–361.
7. van Valkengoed IG, Morre SA, van den Brule AJ, Meijer
CJ, Bouter LM, Boeke AJ. Overestimation of complication
rates in evaluations of Chlamydia trachomatis screening
programmes—implications for cost-effectiveness analyses.
Int J Epidemiol 2004; 33: 416–425.
8. Centers for Disease Control and Prevention, American
Society for Reproductive Medicine, Society for Assisted
Reproductive Technology. 2005 Assisted Reproductive
Technology Success Rates. National Summary and Fertility
Clinic Reports, Atlanta: Centers for Disease Control and
Prevention, 2007.
9. Suchland RJ, Stamm WE. Simplified microtiter cell culture
method for rapid immunotyping of Chlamydia trachomatis.
J Clin Microbiol 1991; 29: 1333–1338.
10. Wang SP, Kuo CC, Barnes RC, Stephens RS, Grayston JT.
Immunotyping of Chlamydia trachomatis with monoclonal
antibodies. J Infect Dis 1985; 152: 791–800.
11. Black CM, Tharpe JA, Russell H. Distinguishing Chlamydia
species by restriction analysis of the major outer mem-
brane protein gene. Mol Cell Probes 1992; 6: 395–400.
12. Frost EH, Deslandes S, Veilleux S, Bourgaux-Ramoisy D.
Typing Chlamydia trachomatis by detection of restriction
fragment length polymorphism in the gene encoding the
major outer membrane protein. J Infect Dis 1991; 163: 1103–
1107.
Pedersen et al. VNTR typing of Chlamydia trachomatis 651
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 644–652
13. Frost EH, Deslandes S, Bourgaux-Ramoisy D. Chlamydia
trachomatis serovars in 435 urogenital specimens typed by
restriction endonuclease analysis of amplified DNA.
J Infect Dis 1993; 168: 497–501.
14. Lan J, Walboomers JM, Roosendaal R et al. Direct detection
and genotyping of Chlamydia trachomatis in cervical
scrapes by using polymerase chain reaction and restriction
fragment length polymorphism analysis. J Clin Microbiol
1993; 31: 1060–1065.
15. Jonsdottir K, Kristjansson M, Hjaltalin OJ, Steingrimsson
O. The molecular epidemiology of genital Chlamydia
trachomatis in the greater Reykjavik area, Iceland. Sex
Transm Dis 2003; 30: 249–256.
16. Lan J, Ossewaarde JM, Walboomers JM, Meijer CJ, van den
Brule AJ. Improved PCR sensitivity for direct genotyping
of Chlamydia trachomatis serovars by using a nested PCR.
J Clin Microbiol 1994; 32: 528–530.
17. Lysen M, Osterlund A, Rubin CJ, Persson T, Persson I,
Herrmann B. Characterization of ompA genotypes by
sequence analysis of DNA from all detected cases of
Chlamydia trachomatis infections during 1 year of contact
tracing in a Swedish County. J Clin Microbiol 2004; 42:
1641–1647.
18. Millman K, Black CM, Johnson RE et al. Population-based
genetic and evolutionary analysis of Chlamydia trachomatis
urogenital strain variation in the United States. J Bacteriol
2004; 186: 2457–2465.
19. Pedersen LN, Kjaer HO, Moller JK, Orntoft TF, Ostergaard
L. High-resolution genotyping of Chlamydia trachomatis
from recurrent urogenital infections. J Clin Microbiol 2000;
38: 3068–3071.
20. Wongworapat K, Veeraseatakul P, Jitvacharanun K,
Leechanachai P. Genotype distribution of genital Chla-
mydia trachomatis in Chiang Mai, Thailand. Southeast Asian
J Trop Med Public Health 2002; 33 (suppl 3): 133–138.
21. Kjaer HO, Dimcevski G, Hoff G, Olesen F, Ostergaard L.
Recurrence of urogenital Chlamydia trachomatis infection
evaluated by mailed samples obtained at home: 24 weeks’
prospective follow up study. Sex Transm Infect 2000; 76:
169–172.
22. Klint M, Fuxelius HH, Goldkuhl RR et al. High-resolution
genotyping of Chlamydia trachomatis strains by multilocus
sequence analysis. J Clin Microbiol 2007; 45: 1410–1414.
23. Keim P, Van Ert MN, Pearson T, Vogler AJ, Huynh LY,
Wagner DM. Anthrax molecular epidemiology and
forensics: using the appropriate marker for different
evolutionary scales. Infect Genet Evol 2004; 4: 205–213.
24. Levinson G, Gutman GA. Slipped-strand mispairing: a
major mechanism for DNA sequence evolution. Mol Biol
Evol 1987; 4: 203–221.
25. Millar BC, Xu J, Moore JE. Risk assessment models and
contamination management: implications for broad-range
ribosomal DNA PCR as a diagnostic tool in medical bac-
teriology. J Clin Microbiol 2002; 40: 1575–1580.
26. Hunter PR, Gaston MA. Numerical index of the discrim-
inatory ability of typing systems: an application of
Simpson’s index of diversity. J Clin Microbiol 1988; 26:
2465–2466.
27. Hunter PR. Reproducibility and indices of discriminatory
power of microbial typing methods. J Clin Microbiol 1990;
28: 1903–1905.
28. Struelens MJ. Consensus guidelines for appropriate use
and evaluation of microbial epidemiologic typing systems.
Clin Microbiol Infect 1996; 2: 236 [Erratum from Volume 2
Number 1, page 5].
29. Struelens MJ. Consensus guidelines for appropriate use
and evaluation of microbial epidemiologic typing systems.
Clin Microbiol Infect 1996; 2: 2–11.
30. Kowalchuk GA, Gerards S, Woldendorp JW. Detection
and characterization of fungal infections of Ammophila
arenaria (marram grass) roots by denaturing gradient gel
electrophoresis of specifically amplified 18s rDNA. Appl
Environ Microbiol 1997; 63: 3858–3865.
31. Muyzer G, de Waal EC, Uitterlinden AG. Profiling of
complex microbial populations by denaturing gradient gel
electrophoresis analysis of polymerase chain reaction-
amplified genes coding for 16S rRNA. Appl Environ
Microbiol 1993; 59: 695–700.
32. Hammerschmidt S, Muller A, Sillmann H et al. Capsule
phase variation in Neisseria meningitidis serogroup B by
slipped-strand mispairing in the polysialyltransferase
gene (siaD): correlation with bacterial invasion and the
outbreak of meningococcal disease. Mol Microbiol 1996; 20:
1211–1220.
33. Waite RD, Struthers JK, Dowson CG. Spontaneous
sequence duplication within an open reading frame of the
pneumococcal type 3 capsule locus causes high-frequency
phase variation. Mol Microbiol 2001; 42: 1223–1232.
34. van Ham SM, van Alphen L, Mooi FR, van Putten JP.
Phase variation of H. influenzae fimbriae: transcriptional
control of two divergent genes through a variable com-
bined promoter region. Cell 1993; 73: 1187–1196.
652 Clinical Microbiology and Infection, Volume 14 Number 7, July 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 644–652
